Oppenheimer assumed coverage of Allogene Therapeutics with an Outperform rating and price target of $11, down from $13. Translational data alongside the recent experience of CAR-Ts in autoimmunity suggest that CAR-Ts do well in low-disease settings, the analyst tells investors in a research note. The firm says ALLO-329 is on track for a new drug filing in Q1 of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
- Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Allogene activates three cancer centers as first sites for Phase 2 ALPHA3 trial